Last updated: October 8, 2026
Lamisil AT is a terbinafine hydrochloride 1% topical antifungal product used primarily for athlete's foot, jock itch, and ringworm. Its commercial position depends less on active-ingredient differentiation than on vehicle performance, patient convenience, drying time, cosmetic acceptability, packaging, and regulatory execution.
The strongest excipient opportunities are alcohol-free or low-irritation creams, rapid-drying film-forming solutions, spray systems, multidose packaging, and formulations that improve adherence on the feet and between the toes. Terbinafine itself is a mature generic active ingredient, so formulation and delivery-system protection are more commercially relevant than composition-of-matter exclusivity.
What is the Lamisil AT formulation?
Lamisil AT products use terbinafine hydrochloride at a 1% concentration. The principal U.S. cream formulation contains a conventional oil-in-water emulsion with fatty alcohols, an emollient, a surfactant, an alkalizing agent, preservative support, and purified water.
Lamisil AT 1% cream excipients
Public U.S. labeling identifies the following inactive ingredients for Lamisil AT cream:
| Excipient |
Functional role |
| Benzyl alcohol |
Preservative and solvent |
| Cetyl alcohol |
Consistency agent and emollient |
| Cetyl palmitate |
Emollient and texture modifier |
| Isopropyl myristate |
Emollient and penetration-supporting vehicle |
| Polysorbate 60 |
Nonionic emulsifier |
| Sodium hydroxide |
pH adjustment |
| Stearyl alcohol |
Emulsion stabilizer and consistency agent |
| Purified water |
Continuous aqueous phase |
The formulation is designed to spread across affected skin and maintain acceptable stability for a consumer topical product. The fatty alcohol system contributes body and skin feel. Isopropyl myristate supports spreadability but can create a richer or more occlusive sensory profile than some consumers prefer. Benzyl alcohol may create irritation or sensitization concerns in susceptible users.
Source: DailyMed, Lamisil AT terbinafine hydrochloride cream label.[1]
What excipient functions matter most for terbinafine topical products?
The main formulation targets are drug release, skin deposition, drying speed, irritation control, and user compliance.
Solubility and drug release
Terbinafine hydrochloride is suitable for topical delivery, but release depends on the vehicle, pH, solvent system, particle state, and emulsion structure. A formulation that retains terbinafine too strongly in the oil phase may reduce release into the stratum corneum. A vehicle with excessive aqueous dilution may reduce substantivity after application.
Formulators should evaluate:
- Terbinafine hydrochloride solubility in the selected vehicle
- Drug crystallization during shelf life
- In vitro release rate
- Skin permeation and retention
- pH drift
- Particle-size distribution if a suspension is used
- Compatibility with the package and applicator
For an antifungal intended to remain in the outer skin layers, high systemic penetration is not the principal objective. Retention in the stratum corneum and affected epidermal tissue is usually more commercially relevant than maximizing transdermal flux.
Skin feel and irritation
Consumers often discontinue topical antifungals because of greasiness, stinging, residue, or slow drying. Excipient selection therefore affects the effective commercial performance of the medicine even when the active ingredient and concentration remain unchanged.
Potential improvements include:
- Replacing or reducing benzyl alcohol where regulatory and preservative requirements permit
- Reducing heavy fatty alcohol content
- Using lightweight esters or volatile carriers
- Introducing barrier-supporting emollients at controlled levels
- Using humectants only where they do not increase tack or prolong wetness
- Optimizing pH for skin tolerability and terbinafine stability
A lower-irritation formulation could support sensitive-skin positioning, although any therapeutic or dermatological claim would require appropriate evidence and labeling review.
What formulations are protected or commercially differentiated by excipients?
The original Lamisil AT cream is a conventional emulsion. The most attractive commercial differentiation would come from dosage-form or delivery-system changes rather than minor substitutions within the existing cream.
Creams and emulsions
A next-generation cream could target:
- Faster absorption
- Lower residue
- Reduced greasiness
- Lower preservative burden
- Improved application between toes
- Better compatibility with socks and footwear
The commercial risk is that a cream remains difficult to distinguish from numerous generic terbinafine creams. A new excipient combination would need a measurable benefit, such as improved drying time, lower tack, higher skin retention, or improved patient preference.
Gels
Hydroalcoholic or nonalcoholic gels can provide rapid spreading and a lighter sensory profile. Carbomers, acrylate polymers, cellulose derivatives, and suitable neutralizers can create a gel vehicle, but the system must control:
- Terbinafine solubility
- Alcohol-related stinging
- Polymer compatibility
- Drying behavior
- Flaking or film formation
- Viscosity after storage
Gels may be attractive for athlete's foot because they can feel less occlusive than creams. Their weakness is potential irritation on fissured or inflamed skin.
Sprays
Sprays can improve reach and convenience, particularly for interdigital areas and consumers who prefer limited hand contact. Commercially relevant excipient and package variables include:
- Ethanol or alternative solvent level
- Propellant selection
- Valve and actuator design
- Spray plume
- Droplet size
- Evaporation rate
- Flammability classification
- Compatibility with plastics and elastomers
A spray can command a price premium, but it carries higher package and manufacturing complexity than a tube cream. It also requires careful control of inhalation and flammability considerations.
Film-forming solutions
Film-forming systems use polymers that leave a thin layer after evaporation. Candidate materials include acrylate copolymers, povidone derivatives, cellulose polymers, and other cosmetic or pharmaceutical film formers.
The commercial proposition is a less frequent application or better persistence on the skin. The technical risks include cracking, pilling, slow removal, residue on socks, and uneven dosing.
Foams and mousse systems
Foams can provide rapid coverage and a dry sensory profile. They require more complex packaging and may need volatile solvents, propellants, or specialized foam stabilizers. Foam is a higher-cost opportunity with potentially stronger differentiation, but the regulatory and manufacturing burden is greater than for a cream or gel.
How does Lamisil AT compare with competing terbinafine formulations?
Lamisil AT competes with generic terbinafine creams, sprays, gels, and other topical antifungals such as clotrimazole, miconazole, tolnaftate, and butenafine products.
| Product type |
Typical consumer benefit |
Excipient opportunity |
Commercial limitation |
| Terbinafine cream |
Familiar, low-cost, broad availability |
Lower residue, improved spreadability |
Weak differentiation |
| Terbinafine gel |
Lightweight feel, rapid spreading |
Alcohol-free gel, low-tack polymer system |
Potential stinging and drying |
| Terbinafine spray |
Hands-free application, broad coverage |
Spray plume and evaporation optimization |
Higher package cost |
| Film-forming solution |
Persistence and convenience |
Durable, flexible polymer film |
Residue and cracking risk |
| Clotrimazole cream |
Established antifungal category |
Barrier-supportive cream systems |
Often requires longer treatment |
| Miconazole cream or powder |
Multiple dosage forms |
Powder and moisture-control systems |
Different treatment positioning |
| Tolnaftate liquid or cream |
Drying and broad consumer recognition |
Fast-drying liquid vehicles |
Lower perceived potency in some markets |
Terbinafine products are generally positioned around shorter treatment courses than several azole comparators. That claim depends on the indication, dosage form, label, and jurisdiction. Companies should avoid assuming that a new excipient system permits a shorter regimen without clinical or regulatory support.
What is the FDA regulatory status of Lamisil AT?
In the United States, topical antifungal products are regulated under the FDA’s OTC topical antifungal framework. The relevant regulation identifies active ingredients and conditions for marketing, including terbinafine hydrochloride at a 1% concentration for specified indications.[2]
The regulatory implications are material:
- A product that remains within the applicable OTC monograph conditions may avoid the full approval burden associated with a new prescription drug application.
- A new dosage form, delivery technology, indication, strength, or labeling claim may require a different regulatory pathway.
- Excipients must remain appropriate for the route, dose, product design, and packaging.
- The finished product must meet stability, microbiological, quality, and labeling requirements.
- A change in vehicle can alter bioavailability, irritation, dosing, or treatment performance.
A monograph pathway does not eliminate formulation risk. A reformulated terbinafine product may still require comparative performance data, stability studies, preservative-effectiveness testing, container-closure studies, and human tolerability work.
What is the Orange Book status of Lamisil AT?
Lamisil AT cream is an OTC topical product and is not typically evaluated as an Orange Book-listed prescription product. The Orange Book is principally used for approved prescription drug products and their listed patents and exclusivity.[3]
As a result, the main intellectual-property issues for a Lamisil AT competitor are likely to involve:
- Formulation patents
- Spray or applicator patents
- Film-forming delivery systems
- Packaging patents
- Manufacturing processes
- Trademark rights
- Trade dress
- Jurisdiction-specific regulatory exclusivity
The original terbinafine active-ingredient patent estate is mature. New opportunities would depend on claims directed to a specific formulation, delivery system, manufacturing process, or use that satisfies novelty, non-obviousness, enablement, and written-description requirements.
When does Lamisil AT lose exclusivity?
The core commercial exclusivity for terbinafine topical products has already matured in the United States and other major markets. Generic terbinafine products are widely available.
Lamisil AT therefore does not rely primarily on conventional small-molecule patent exclusivity. Its remaining commercial protections are more likely to be:
- Brand recognition
- Consumer trust
- Retail placement
- Packaging
- Formulation-specific differentiation
- Trademark protection
- Distributor relationships
- International market positioning
No conventional Paragraph IV event is central to current U.S. Lamisil AT commercial risk because the product is marketed as an OTC topical product rather than as a typical Orange Book-listed prescription product. Generic competition is already established rather than dependent on a future patent challenge.
What patent opportunities exist for Lamisil AT excipients and delivery systems?
The strongest patent candidates would claim a defined combination of active ingredient, excipients, performance parameters, and manufacturing conditions.
Potential claim areas
- Terbinafine hydrochloride in a low-irritation emulsion
- A specified solvent and polymer system
- A film-forming terbinafine composition with controlled drying time
- A spray formulation with defined droplet-size distribution
- A package-actuator combination that improves interdigital delivery
- A formulation with specified skin-retention or release characteristics
- A preservative-reduced product with validated microbiological protection
- A manufacturing process that limits terbinafine crystallization
- A stable formulation across defined temperature and humidity ranges
Narrow excipient substitution claims are vulnerable to obviousness challenges when the ingredients are established pharmaceutical or cosmetic excipients. Stronger protection usually requires a demonstrated technical effect tied to a defined composition or process.
Which companies are challenging or competing with Lamisil AT?
Competition comes from several groups:
- Generic manufacturers selling terbinafine cream, gel, and spray products
- Consumer-health companies marketing clotrimazole, miconazole, and tolnaftate
- Private-label retailers
- Online pharmacies and marketplace sellers
- Contract manufacturers supplying retailer-branded antifungal products
- Specialty topical-drug companies developing improved delivery systems
Generic competition is strongest in standard 1% cream. Differentiation is more feasible in sprays, films, foams, applicators, and convenience-oriented packaging.
What licensing and commercial opportunities exist?
Potential licensing targets include:
- A ready-to-use film-forming platform with terbinafine compatibility data.
- A low-irritation vehicle supported by comparative human-use studies.
- A spray package that delivers consistent dosing without clogging.
- A contract-manufacturing platform for OTC antifungal creams and sprays.
- A retailer-exclusive product with differentiated packaging and dosage form.
- A formulation that reduces application frequency, subject to regulatory support.
- A combination product addressing fungal infection and associated skin-barrier symptoms, if permitted by the applicable regulatory pathway.
The most practical route is likely a line extension rather than a new active ingredient. A manufacturer could use the terbinafine 1% platform and introduce a spray, gel, or film product with separate branding and packaging.
What generic launch risks exist for a new Lamisil AT formulation?
The principal risks are technical and commercial rather than Paragraph IV litigation risks.
| Risk |
Business impact |
Mitigation |
| Poor terbinafine release |
Reduced clinical performance |
In vitro release and skin-retention studies |
| Irritation from alcohol or solvent |
Lower repeat use |
Human tolerability screening |
| Cracking or pilling |
Poor consumer acceptance |
Film-flexibility and wear testing |
| Clogged spray actuator |
Product complaints and returns |
Accelerated package testing |
| Preservative failure |
Microbiological risk |
Challenge testing and stability studies |
| Excipient incompatibility |
Loss of potency or phase separation |
Extractables, leachables, and compatibility studies |
| Weak differentiation |
Price-based competition |
Consumer preference and performance data |
| Labeling limitations |
Restricted claims |
Early regulatory classification review |
| Retailer substitution |
Margin pressure |
Distinct format, packaging, and channel strategy |
How strong is the Lamisil AT patent estate?
The legacy patent estate for terbinafine is commercially weak as a barrier to generic topical entry because the active ingredient and standard topical forms are mature. The potential strength lies in newly developed formulation and delivery patents.
A new estate would be strongest if it has:
- Composition claims covering a non-obvious excipient combination
- Process claims linked to a reproducible technical benefit
- Performance data showing improved skin retention or release
- Claims that cover multiple dosage forms or package configurations
- Patent filings in the United States, Europe, Japan, China, Canada, Australia, and major Latin American markets
- Freedom-to-operate analysis against existing topical antifungal patents
Geographic coverage should match the commercial plan. A global patent filing strategy may be excessive for a low-price cream but justified for a differentiated spray, film, or proprietary applicator.
Key Takeaways
- Lamisil AT uses terbinafine hydrochloride 1%, with a conventional cream vehicle based on fatty alcohols, isopropyl myristate, polysorbate 60, benzyl alcohol, water, sodium hydroxide, and related excipients.
- The active ingredient is mature, and generic competition is established.
- The main commercial opportunity is vehicle and delivery-system differentiation.
- Low-residue creams, alcohol-free gels, sprays, films, and foams offer the clearest line-extension opportunities.
- A new formulation must demonstrate more than an excipient substitution. It needs measurable benefits in release, retention, drying, irritation, dosing, or adherence.
- Orange Book and Paragraph IV strategies are less central than formulation patents, package patents, trademarks, and OTC regulatory execution.
- The best licensing targets are platforms that combine terbinafine compatibility, package performance, stability, and human-use data.
FAQs About Lamisil AT Excipients and Commercial Strategy
Can benzyl alcohol be removed from a Lamisil AT formulation?
Yes, but removal would require a replacement preservative or a formulation and package design that supports microbiological control. The replacement must be compatible with terbinafine, the vehicle, the intended route, and applicable regulatory requirements.
Is an alcohol-free terbinafine gel commercially attractive?
Yes. An alcohol-free gel could target consumers who want a light, fast-spreading product without alcohol-related stinging. Its success would depend on drug solubility, drying time, tack, stability, and tolerability.
Can a new excipient combination receive a patent?
Potentially. A patent is more defensible when the combination produces an unexpected technical result, such as improved terbinafine skin retention, reduced irritation, enhanced stability, or controlled drying. Routine substitution of known excipients is less likely to provide strong protection.
Would a terbinafine spray require FDA approval?
The pathway depends on the final formulation, active ingredient concentration, indication, labeling, and whether the product fits the applicable OTC framework. A spray may require regulatory review beyond a conventional monograph-compliant cream if its formulation, delivery system, or claims introduce material differences.
What is the highest-value excipient opportunity for Lamisil AT?
A low-irritation, fast-drying, low-residue delivery system with strong skin retention is likely the highest-value opportunity. A spray or film-forming product could command greater differentiation than another conventional terbinafine cream.
References
- National Library of Medicine. (n.d.). DailyMed: Lamisil AT terbinafine hydrochloride cream label. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). 21 C.F.R. § 333.210: Topical antifungal drug products for over-the-counter human use.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.
